There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on KalVista Pharmaceuticals (KALV) and scPharmaceuticals (SCPH) with bullish sentiments.
KalVista Pharmaceuticals (KALV)
In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on KalVista Pharmaceuticals, with a price target of $30.00. The company’s shares closed last Wednesday at $12.12.
According to TipRanks.com, Fein is a 5-star analyst with an average return of 11.6% and a 46.9% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Constellation Pharmaceuticals, and Proteostasis Therapeutics.
Currently, the analyst consensus on KalVista Pharmaceuticals is a Moderate Buy with an average price target of $27.50, which is an 118.4% upside from current levels. In a report released yesterday, Needham also maintained a Buy rating on the stock with a $25.00 price target.
See today’s analyst top recommended stocks >>
scPharmaceuticals (SCPH)
H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on scPharmaceuticals today and set a price target of $15.00. The company’s shares closed last Wednesday at $7.17.
According to TipRanks.com, Tsao is a 5-star analyst with an average return of 9.2% and a 52.6% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, Protagonist Therapeutics, and Minerva Neurosciences.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for scPharmaceuticals with a $13.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
